Cardiometabolic Disease Prevention

Future Strategies to Prevent Heart Failure

by Prateek Chopra | May 22, 2026 | Cardiology Conferences | ESC-HF 2026 Heart failure (HF) prevention is increasingly focused on early intervention targeting cardiometabolic, inflammatory, renal, and neurohormonal pathways before the development of symptomatic disease. Emerging evidence suggests that integrated preventive strategies can substantially reduce incident HF, cardiovascular (CV) events, and progression of chronic kidney disease (CKD). The findings were […]

Future Strategies to Prevent Heart Failure Read Post »

Leave a Comment / ESC-HF Day 2 / bluetree.healthcare@gmail.com / July 30, 2026 / Aldosterone Synthase Inhibitors (ASI), Cardiometabolic Disease Prevention, Heart Failure Prevention, Precision Cardiovascular Medicine, SGLT2 Inhibitors

Which Drugs Prevent Heart Failure?

by Prateek Chopra | May 21, 2026 | Cardiology Conferences | ESC-HF 2026 Heart failure (HF) prevention has evolved from traditional risk-factor management to targeted pharmacologic intervention across the HF continuum. Contemporary evidence supports multiple cardiometabolic therapies that prevent incident HF, delay progression from pre-HF to symptomatic disease, and reduce HF hospitalization (HFH). The findings were presented at Heart Failure 2026,